PubMed HealthSearch

PubMed · 9325118

Analyzing Neuronal Processing Locus in Stimulus-Response Association Tasks

Abstract

If a neuron is being recorded while a trained animal performs a 2x2 stimulus-response association task, how can we decide whether it is related more to the encoding and analysis of the sensory stimulus, to the preparation and execution of the motor response, or to the animal's decision that associates the two? The difficulty arises because, within a single task, stimulus and response are intrinsically confounded per task instruction; it is only through proper analysis of errors in performance (behavioral noise) and variance in recorded neural activity (neuronal noise) that one can identify the sensorimotor significance of such activity. A quantitative technique is proposed here, based on the framework of signal detection theory, to determine the sensorimotor "locus" of a neural process when recorded simultaneously with the animal's performance on a trial-by-trial basis. The premise is that a pure sensory process should be influenced only by the nature of the sensory stimulus regardless of the nature of the behavioral response, and vice versa for a pure motor process. From the recorded neural activity, we calculate the prediction or discriminability (by an ideal operator) for the stimulus categories and for the response categories. These discriminability values are then compared with each other to infer whether the neural process is more related to stimulus or to response. An index is derived that quantitatively specifies the processing locus of a given neural process along the sensorimotor continuum, with pure sensory and pure motor processes at the two extremes. In between lies the locus of decision-related processes whose activities allow equal (but not chance) prediction for stimulus and response categories. The technique is applied to single-unit activities recorded in monkey primary motor cortex (MI) while the monkey performed a simple go/nogo task involving visual stimulus and hand/wrist movement. We find that sensorimotor indices of MI neurons are widely distributed, with a preponderance of motor-related units (that better predict go/nogo response than go/nogo stimulus) but also sensory-related ones (with predictabilities reversed). Copyright 1997 Academic Press

Explore related subjects

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

J Zhang, A Riehle, J Requin. 1997. Analyzing Neuronal Processing Locus in Stimulus-Response Association Tasks. https://doi.org/10.1006/jmps.1997.1168

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

Effectiveness of high-dose versus standard-dose influenza vaccines against hospitalisation according to frailty risk: a prespecified analysis of the randomised trial DANFLU-2.

BACKGROUND: Frailty is a major risk factor for influenza-related complications and can influence vaccine effectiveness. We aimed to assess the relative vaccine effectiveness (rVE) of high-dose (HD-IIV) versus standard-dose inactivated influenza vaccine (SD-IIV) in older adults aged 65 years or older according to frailty risk. METHODS: This study was a prespecified analysis of DANFLU-2, an open-label, individually randomised trial, conducted in Denmark during three consecutive influenza seasons (2022-23, 2023-24, and 2024-25). Adults aged 65 years or older were randomised (1:1) to the HD-IIV or SD-IIV group. The primary endpoint was hospitalisation for influenza or pneumonia. Frailty was defined according to the validated Hospital Frailty Risk Score (HFRS) based on ICD-10 codes within 10 years before randomisation. Participants were stratified into three HFRS categories, namely low (<5 points), intermediate (5-15 points), and high (>15 points) frailty risk. The rVE of HD-IIV versus SD-IIV against the primary endpoint was assessed across prespecified HFRS categories and treating HFRS as a continuous variable. Pearson's chi-square test was used to compare safety events across frailty risk groups and randomisation groups. FINDINGS: Among 332&#x2009;438 randomised participants (mean age 73&#xb7;7 years [SD 5&#xb7;8]; 161&#x2009;538 [48&#xb7;6%] were female), 276&#x2009;173 (83&#xb7;1%) had low frailty risk, 52&#x2009;395 (15&#xb7;8%) had intermediate frailty risk, and 3861 (1&#xb7;2%) had high frailty risk. The primary endpoint of hospitalisation for influenza or pneumonia occurred in 1424 (0&#xb7;5%) of 276&#x2009;173 participants with low frailty risk, 761 (1&#xb7;5%) of 52&#x2009;395 with intermediate frailty risk, and 163 (4&#xb7;2%) of 3861 with high frailty risk (relative risk [RR] for intermediate vs low frailty risk 2&#xb7;8 [95% CI 2&#xb7;6-3&#xb7;1]; RR for high vs low frailty risk 8&#xb7;2 [7&#xb7;0-9&#xb7;6]). HFRS as a continuous variable significantly modified the effect of HD-IIV versus SD-IIV against the primary endpoint with higher rVE estimates with increasing HFRS (pinteraction=0&#xb7;020). The rVE was 0&#xb7;2% (95% CI -10&#xb7;8 to 10&#xb7;2) among those with low frailty risk, 13&#xb7;1% (-0&#xb7;4 to 24&#xb7;8) among those with intermediate frailty risk, and 19&#xb7;9% (-10&#xb7;3 to 42&#xb7;1) among those with high frailty risk. No significant interaction was observed when HFRS was assessed according to the prespecified categorical frailty groups (pinteraction=0&#xb7;17). The proportion of participants with at least one serious adverse event increased across frailty risk groups (13&#x2009;366 [4&#xb7;8%] of 275&#x2009;795 for low frailty risk, 5475 [10&#xb7;5%] of 52&#x2009;315 for intermediate frailty risk, and 777 [20&#xb7;2%] of 3850 for high frailty risk; p<0&#xb7;0001), with similar proportions of serious adverse events in the HD-IIV and SD-IIV groups for each frailty risk group. INTERPRETATION: Among adults aged 65 years or older in Denmark, frailty risk might modify the effects of HD-IIV versus SD-IIV against hospitalisation for influenza or pneumonia, with higher rVE estimates with increasing frailty risk. These findings might support considering high-dose influenza vaccines for frail older adults. However, effect modification was not evident when frailty was assessed using prespecified categorical subgroups, and subgroup-specific estimates were imprecise, with 95% CIs crossing the null. These results should be considered exploratory, warranting further investigation. FUNDING: The DANFLU-2 trial was funded by Sanofi.

Journal Article